Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaokui Mo

Showing results (191-200 of 207) with videos related to

Pageof 21
Sort By:
Cell Reports|July 20, 2022
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivityChi-Ling Chiang, Eileen Y Hu, Lingqian Chang, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Blood Advances|September 30, 2024
CD37 in acute myeloid leukemia: a novel surface target for drug deliveryErin Jeremy, Esthela Artiga, Sara Elgamal, et al.
American Journal of Respiratory Cell and Molecular Biology|April 10, 2025
Docosahexaenoic Acid and Its Metabolites Protects Against Ozone-induced Pulmonary InflammationMichael J Yaeger, Tyson Ngatikaura, Natali Zecchino, et al.
Blood|November 17, 2021
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemiaSwagata Goswami, Rajeswaran Mani, Jessica Nunes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell CarcinomaElizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
Frontiers in Immunology|January 2, 2026
Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearanceBryan C Remaily, Greg Young, Hannah Lathrop, et al.
Nature Cell Biology|October 16, 2012
Canonical and atypical E2Fs regulate the mammalian endocycleHui-Zi Chen, Madhu M Ouseph, Jing Li, et al.
Cancer Cell|May 26, 2012
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signalsRosa Lapalombella, Yuh-Ying Yeh, Liwen Wang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 26, 2025
Extracellular Vesicular Delta-Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer DiagnosisHong Li, Chi-Ling Chiang, Kwang Joo Kwak, et al.
Pageof 21

Showing results (191-200 of 207) with videos related to

Sort By:
Pageof 21
Cell Reports|July 20, 2022
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivityChi-Ling Chiang, Eileen Y Hu, Lingqian Chang, et al.
Leukemia|November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemiaSteven Sher, Ethan Whipp, Janek Walker, et al.
Blood Advances|September 30, 2024
CD37 in acute myeloid leukemia: a novel surface target for drug deliveryErin Jeremy, Esthela Artiga, Sara Elgamal, et al.
American Journal of Respiratory Cell and Molecular Biology|April 10, 2025
Docosahexaenoic Acid and Its Metabolites Protects Against Ozone-induced Pulmonary InflammationMichael J Yaeger, Tyson Ngatikaura, Natali Zecchino, et al.
Blood|November 17, 2021
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemiaSwagata Goswami, Rajeswaran Mani, Jessica Nunes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2019
A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell CarcinomaElizabeth L McMichael, Brooke Benner, Lakhvir S Atwal, et al.
Frontiers in Immunology|January 2, 2026
Tumor intrinsic properties dictate Fc receptor expression and cancer cachexia associated increase in checkpoint inhibitor clearanceBryan C Remaily, Greg Young, Hannah Lathrop, et al.
Nature Cell Biology|October 16, 2012
Canonical and atypical E2Fs regulate the mammalian endocycleHui-Zi Chen, Madhu M Ouseph, Jing Li, et al.
Cancer Cell|May 26, 2012
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signalsRosa Lapalombella, Yuh-Ying Yeh, Liwen Wang, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|April 26, 2025
Extracellular Vesicular Delta-Like Ligand 3 and Subtype Transcription Factors for Small Cell Lung Cancer DiagnosisHong Li, Chi-Ling Chiang, Kwang Joo Kwak, et al.
Pageof 21